- Case report
- Open Access
- Open Peer Review
Presumed topiramate retinopathy: a case report
© The Author(s). 2016
- Received: 4 February 2016
- Accepted: 13 June 2016
- Published: 1 August 2016
We report a case of peripheral pigmentary retinopathy and visual field loss following topiramate use for uncontrolled seizures. Such side effects have not been well documented despite the increasing use of topiramate in the past 10 years. A thorough search of available English literature revealed only a small number of reports of topiramate-induced retinopathy or visual field defects in humans. One similar case has been described. We are concerned about the possible rare instances of this occurrence in future patients and hence would like to propose a presumed correlation.
A 48-year-old Chinese woman developed blurred vision after 9 months of topiramate use. Her visual acuity dropped from 1.2 to 0.7 in both eyes, with bilateral diffuse pigmentary retinopathy and a constricted visual field. Despite an improvement in visual acuity after cessation of the drug, the other clinical findings remained. The temporal relationship between the initiation of topiramate and the visual disturbance suggests that topiramate could be the cause of such signs and symptoms.
Topiramate potentially causes pigmentary retinopathy and constricted visual field.
- Pigmentary retinopathy
- Vision disorder
- Visual field
Topiramate is a sulfurated drug approved by the US Food and Drug Administration (FDA) for the treatment of partial seizures, migraine, depression, and neuropathic pain. The off-label use of topiramate as a weight-reducing agent has gained popularity. The common dosage used is in the range of 50 to 400 mg per day. Several ocular side effects with explainable mechanisms have been described by the World Health Organization , including acute myopia, diplopia, and shallow anterior chamber with angle closure. Other severe ocular side effects were mentioned in previous case reports but the mechanism is not well understood . We report a case of presumed correlation between topiramate and bilateral diffuse pigmentary retinopathy with visual field loss 9 months after initiation of topiramate therapy.
A 48-year-old Chinese woman with a history of a right parasagittal meningioma with surgery and gamma knife excision done, was first put on valproate but then stepped up to topiramate 26 months later for uncontrolled seizures. The initial dose was topiramate 25 mg twice a day, which was eventually stepped up to 100 mg twice a day for adequate seizure control. She was referred to our ophthalmology clinic for dry eyes before the use of topiramate, with an examination showing a baseline visual acuity of 1.2 in both eyes with unremarkable anterior segment and fundoscopy examination. There was no family history of retinal diseases.
All investigations were repeated 1 year after discontinuation of topiramate. Bilateral diffuse pigmentary retinopathy was still present, with visual field test showing similar peripheral constriction, although her visual acuity improved back to 1.0 in both eyes and she reported subjective improvement in vision.
It has been documented that topiramate can cause ciliochoroidal effusion syndrome, leading to acute myopia, acute angle closure, and macular striae . However, a thorough search of available English literature revealed only a small number of reports of topiramate-induced retinopathy or visual field defects in humans. One similar case has been described [4, 5].
The main visual abnormality found in our patient was bilateral diffuse pigmentary retinopathy and constricted visual field. Without family history of retinal disease, and as our patient was only on topiramate monotherapy while visual blurring occurred, no other risk factors for developing such retinopathy could be identified other than topiramate drug use. We cannot entirely exclude the possibility that the retinal pathology was related to the previous treatment with valproate; however, valproate is a commonly used antiepileptic and no such diseases have been documented in literature. The time course of development of visual impairment after 9 months’ use of topiramate, and the improvement of our patient’s visual acuity after discontinuation of the drug suggests that topiramate is the top etiological factor. Hence, we presume her pigmentary retinopathy with the constricted visual field was caused by topiramate drug toxicity. However, as all structural and functional macular parameters were normal, the reason why there was a visual acuity drop remained unclear. A possible explanation could be that the pigmentary retinopathy was noted and topiramate was immediately stopped at an early stage, when definite signs of maculopathy could not be demonstrated yet.
A proposed mechanism of how topiramate leads to reduction in retinal function has been demonstrated in a rabbit study . Histopathological analyses found extensive accumulation of gamma-aminobutyric acid (GABA) in the inner retina, and ERG found reduction in 30 Hz flicker b-wave amplitude. No human studies have been done so far hence the actual mechanism remains uncertain.
Topiramate is an antiepileptic drug that works on multiple mechanisms, including enhancement of GABA receptor activity. Vigabatrin is another GABAergic antiepileptic drug that is known to cause irreversible visual field defects in more than 30 % of patients . Hence, it is reasonable to postulate that topiramate can cause retinal toxicity similar to that caused by vigabatrin. Further investigation is required before the suspected correlation can be confirmed.
Topirmate potentially causes pigmented retinopathy and constricted visual field. Although visual acuity returned to normal after immediate cessation of the drug after visual abnormality occurred, ophthalmological findings did not show significant improvement. Hence it is difficult to comment whether or not such pathologies are reversible after discontinuation of drug. Whether the retinopathy is dose-related, whether there is any correlation with duration of treatment, the risk factors for developing such retinopathy, and whether routine screening is necessary, would rely on future studies to answer the above questions.
ERG, electroretinogram; FDA, Food and Drug Administration; GABA, gamma-aminobutyric acid; ISCEV, International Society for Clinical Electrophysiology of Vision
We thank Mr Raymond Wu who performed all the necessary imaging for documentation of this rare condition. We would also like to acknowledge our patient on whom this case report is based.
Availability of data and materials
The data presented in this manuscript are fully anonymous.
TY summarized the patient’s clinical data and performed the literature search. All authors interpreted patient data together and came up with the final conclusion. All authors read and approved the final manuscript.
KL and PL are consultant ophthalmologists who subspecialize in vitreoretinal surgery.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275–9.View ArticlePubMedGoogle Scholar
- Asensio-Sanchez VM, Torreblanca-Aguera B, MartinezCalvo S, et al. Severe ocular side effects with Topomax. Arch Soc Esp Ophthalmol. 2006;81:345–8.Google Scholar
- Abtahi MA, Abtahi SH, Fazel F, Roomizadeh P, Etemadifar M, Jenab K, et al. Topiramate and the vision: a systematic review. Clin Ophthalmol. 2012;6:117–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Foroozan R, Buono LM. Foggy visual field defect. Surv Ophthalmol. 2003;48:447–51.View ArticlePubMedGoogle Scholar
- Vaphiades MS, Mason J. Foggy visual field defect. Surv Ophthalmol. 2004;49(2):266–7.View ArticlePubMedGoogle Scholar
- Kjellström S, Bruun A, Isaksson B, Eriksson T, Andréasson S, Ponjavic V. Retinal function and histopathology in rabbits treated with topiramate. Doc Ophthamol. 2006;113:179–86.View ArticleGoogle Scholar
- Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51:2423–31.View ArticlePubMedGoogle Scholar